｜學院特色 College Features｜
雅氏學院-李良雄亞太外科教育紀念中心在陽明交大揭牌 成為亞太區神經外科解剖培訓基地
Aesculap Academy—Lee Liang-Shong Asia-Pacific Surgical Education Memorial Center Launched at NYCU, Establishing a Hub for Neurosurgical Anatomy Training in Asia-Pacific
「雅氏學院—李良雄亞太外科教育紀念中心」於11月19日在陽明交通大學正式揭幕。該學院隸屬於德國柏朗集團(B. Braun Group)，是全球知名外科醫事持續教育機構。陽明交大與台北榮總舉辦的神經外科腦手術解剖教育課程，由於會進口真的人體頭顱，讓神經外科醫師精進顱底手術技巧，每年都有外籍醫師特地來台參與，這一成就吸引德國柏朗集團下的雅氏學院主動尋求合作。此中心，不僅感念李前副校長在神經外科領域的付出，也期待為亞太地區的外科教育與醫療訓練貢獻更多力量。
The Aesculap Academy—Lee Liang-Shong Asia-Pacific Surgical Education Memorial Center was officially inaugurated at NYCU on November 19. Affiliated with the B. Braun Group, the academy is a globally renowned institution for continuing surgical education. The Neurosurgical Cranial Surgery Dissection Training Course, jointly held by NYCU and Taipei Veterans General Hospital (TVGH), has gained recognition for using real human skulls, enabling neurosurgeons to refine their skull base surgical techniques. This exceptional achievement has annually attracted foreign surgeons to Taiwan and drew the attention of the Aesculap Academy under the B. Braun Group, prompting them to actively seek collaboration. The center not only honors the contributions of the late Dr. Lee Liang-Shong, former NYCU vice president, in neurosurgery but also aspires to advance surgical education and medical training across the Asia-Pacific region.
｜校長來信 President’s Letter｜
校長手札第五篇－挫折與韌性
Letters from the President: 05. Adversity and Resilience
人生是一段充滿挑戰和未知的旅程，我們無法預測未來會發生什麼，但我們能夠選擇如何面對。在臨床工作，我見證過病人的生死，然而，真正讓我對死亡產生深刻理解的，卻是我自己的經歷。年輕時，我曾歷經一場重病，這段經歷讓我重新審視生命的意義，也讓我在面對人生的挑戰時，有了更多的思考與感悟。這封信，我想與大家分享這段特殊經歷中的感悟，並談談我對挫折的看法。
Life is a journey filled with challenges and uncertainties. While we cannot always predict what lies ahead, we can choose how to face it. Through my clinical work, I have witnessed both life and death, but it was my own personal experiences that gave me a profound understanding of mortality. When I was young, I endured a severe illness, an ordeal that led me to re-evaluate the meaning of life and deepened my perspective on overcoming challenges. In this letter, I would like to share the insights I gained from this unique experience and my reflections on facing adversity.
｜產學合作 Industry Cooperation｜
聚焦神經免疫治療！陽明交大攜手安立璽榮生醫 運用 AI 輔助開發新藥
NYCU Partners with Elixiron Immunotherapeutics to Revolutionize Neuroimmune Therapy Using AI-Powered Drug Development
為培育台灣生技新藥高階研發人才，陽明交通大學宣布與校友創辦的安立璽榮生醫簽署為期五年的產學合作備忘錄。雙方將聚焦人工智慧輔助新藥開發，推動新穎口服免疫調節藥物 Enrupatinib 的臨床研究與商品化。該藥物目前已在台北榮總展開阿茲海默症第二期臨床試驗，將為新藥開發困境帶來曙光。
In a groundbreaking effort to nurture Taiwan’s next generation of biotech talent, NYCU has signed a five-year industry-academia collaboration agreement with alumni-founded Elixiron Immunotherapeutics. This partnership will leverage artificial intelligence to advance drug development, focusing on the clinical trials and commercialization of Enrupatinib, an innovative oral immune-modulating drug. Currently undergoing Phase II clinical trials for Alzheimer’s disease at Taipei Veterans General Hospital, Enrupatinib offers hope in the challenging landscape of new drug development.